| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Paul J Wellman, Audrea E Elliott, Stephanie Barbee, Chelsie N Hollas, P Shane Clifford, Jack R Natio. Lobeline attenuates progressive ratio breakpoint scores for intracranial self-stimulation in rats. Physiology & behavior. vol 93. issue 4-5. 2008-07-31. PMID:18272188. |
the alkaloid lobeline inhibits the function of vesicular monoamine and dopamine transporters and diminishes the behavioral and neurochemical effects of nicotine and amphetamines. |
2008-07-31 |
2023-08-12 |
rat |
| Patricia Vieyra-Reyes, Marina R Picciotto, Yann S Mineu. Voluntary oral nicotine intake in mice down-regulates GluR2 but does not modulate depression-like behaviors. Neuroscience letters. vol 434. issue 1. 2008-07-03. PMID:18261852. |
repeated exposure to nicotine induces adaptive changes in the central nervous system including the mesolimbic dopamine (da) projections from the ventral tegmental area (vta) to the nucleus accumbens (nac). |
2008-07-03 |
2023-08-12 |
mouse |
| José Antonio López-Moreno, María Scherma, Fernando Rodríguez de Fonseca, Gustavo González-Cuevas, Walter Fratta, Miguel Navarr. Changed accumbal responsiveness to alcohol in rats pre-treated with nicotine or the cannabinoid receptor agonist WIN 55,212-2. Neuroscience letters. vol 433. issue 1. 2008-06-02. PMID:18261849. |
alcohol, nicotine, and cannabinoid acutely increase the activity of the mesolimbic dopamine (da) pathway. |
2008-06-02 |
2023-08-12 |
rat |
| José Antonio López-Moreno, María Scherma, Fernando Rodríguez de Fonseca, Gustavo González-Cuevas, Walter Fratta, Miguel Navarr. Changed accumbal responsiveness to alcohol in rats pre-treated with nicotine or the cannabinoid receptor agonist WIN 55,212-2. Neuroscience letters. vol 433. issue 1. 2008-06-02. PMID:18261849. |
therefore, cannabinoid and nicotine exposure may have important implications on the rewarding effects of alcohol, because these drugs lead to long-lasting changes in accumbal dopamine transmission. |
2008-06-02 |
2023-08-12 |
rat |
| Kathryn O'Leary, Neeraja Parameswaran, J Michael McIntosh, Maryka Qui. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. The Journal of pharmacology and experimental therapeutics. vol 325. issue 2. 2008-05-19. PMID:18305015. |
our results unexpectedly showed that nicotine evokes [(3)h]dopamine release from two alpha3/alpha6beta2* nachr populations, one of which was sensitive to cotinine and the other was not. |
2008-05-19 |
2023-08-12 |
monkey |
| Kathryn O'Leary, Neeraja Parameswaran, J Michael McIntosh, Maryka Qui. Cotinine selectively activates a subpopulation of alpha3/alpha6beta2 nicotinic receptors in monkey striatum. The Journal of pharmacology and experimental therapeutics. vol 325. issue 2. 2008-05-19. PMID:18305015. |
in contrast, cotinine and nicotine elicited equivalent levels of alpha4beta2* nachr-mediated dopamine release. |
2008-05-19 |
2023-08-12 |
monkey |
| Christoph Fehr, Igor Yakushev, Nina Hohmann, Hans-Georg Buchholz, Christian Landvogt, Hanna Deckers, Alexandra Eberhardt, Marie Kläger, Michael N Smolka, Armin Scheurich, Thomas Dielentheis, Lutz G Schmidt, Frank Rösch, Peter Bartenstein, Gerhard Gründer, Mathias Schreckenberge. Association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. The American journal of psychiatry. vol 165. issue 4. 2008-05-14. PMID:18316420. |
association of low striatal dopamine d2 receptor availability with nicotine dependence similar to that seen with other drugs of abuse. |
2008-05-14 |
2023-08-12 |
Not clear |
| Mohammed Shoai. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology. vol 54. issue 2. 2008-05-12. PMID:18054052. |
the cannabinoid receptor subtype (cb1) antagonist rimonabant (sr141716) has been shown to decrease nicotine self-administration and attenuate nicotine-evoked dopamine release in the nucleus accumbens; effects that support recent findings on its clinical efficacy as a smoking cessation aid. |
2008-05-12 |
2023-08-12 |
rat |
| Susanne Nikolaus, Christina Antke, Konstantin Kley, Thorsten D Poeppel, Hubertus Hautzel, Daniela Schmidt, Hans-Wilhelm Mülle. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Reviews in the neurosciences. vol 18. issue 6. 2008-05-02. PMID:18330212. |
interestingly, findings are also consistent with respect to drug abuse: cocaine, amphetamine, methylphenidate, heroin, alcohol and nicotine invariably act via enhancement of dopamine release in dorsal and/ or ventral striatal regions. |
2008-05-02 |
2023-08-12 |
Not clear |
| R Exley, S J Crag. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. British journal of pharmacology. vol 153 Suppl 1. 2008-04-28. PMID:18037926. |
the effects of nicotine on dopamine transmission from mesostriatal dopamine neurons are central to its reinforcing properties. |
2008-04-28 |
2023-08-12 |
Not clear |
| R Exley, S J Crag. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. British journal of pharmacology. vol 153 Suppl 1. 2008-04-28. PMID:18037926. |
we will also review how nicotine, acting via nachr desensitization, promotes the sensitivity of dopamine synapses to activity. |
2008-04-28 |
2023-08-12 |
Not clear |
| R Exley, S J Crag. Presynaptic nicotinic receptors: a dynamic and diverse cholinergic filter of striatal dopamine neurotransmission. British journal of pharmacology. vol 153 Suppl 1. 2008-04-28. PMID:18037926. |
this filtering action might provide a mechanism through which nicotine promotes how burst activity in dopamine neurons facilitates goal-directed behaviour and reinforcement processing. |
2008-04-28 |
2023-08-12 |
Not clear |
| S P David, M R Munafò, M F G Murphy, M Proctor, R T Walton, E C Johnston. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. The pharmacogenomics journal. vol 8. issue 2. 2008-04-10. PMID:17387332. |
genetic variation in the dopamine d4 receptor (drd4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. |
2008-04-10 |
2023-08-12 |
Not clear |
| S P David, M R Munafò, M F G Murphy, M Proctor, R T Walton, E C Johnston. Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch. The pharmacogenomics journal. vol 8. issue 2. 2008-04-10. PMID:17387332. |
smokers of european ancestry (n=720) who participated in a double-blind, randomised, placebo-controlled trial of transdermal nicotine replacement therapy, were genotyped for two functional polymorphisms (variable number of tandem repeats (vntr) and a c to t transition at position -521 (c-521t)) in the dopamine d4 receptor gene (drd4) gene. |
2008-04-10 |
2023-08-12 |
Not clear |
| Neal L Benowit. Neurobiology of nicotine addiction: implications for smoking cessation treatment. The American journal of medicine. vol 121. issue 4 Suppl 1. 2008-04-10. PMID:18342164. |
nicotine acts on these brain nicotinic cholinergic receptors to facilitate neurotransmitter release (dopamine and others), producing pleasure, stimulation, and mood modulation. |
2008-04-10 |
2023-08-12 |
Not clear |
| J Taylor Hays, Jon O Ebbert, Amit Soo. Efficacy and safety of varenicline for smoking cessation. The American journal of medicine. vol 121. issue 4 Suppl 1. 2008-04-10. PMID:18342165. |
nicotine addiction is mediated by stimulation of central alpha(4)beta(2) nachrs by nicotine, which causes the release of dopamine, ultimately leading to the pleasurable effects of smoking. |
2008-04-10 |
2023-08-12 |
Not clear |
| Cindy K Funk, Douglas P Dohrma. Chronic ethanol exposure inhibits dopamine release via effects on the presynaptic actin cytoskeleton in PC12 cells. Brain research. vol 1185. 2008-03-28. PMID:17996852. |
in ethanol-treated cells, dopamine release was inhibited following stimulation by forms of release shown to be pkc-dependent (nicotine, sucrose, and potassium). |
2008-03-28 |
2023-08-12 |
Not clear |
| N L Benowit. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clinical pharmacology and therapeutics. vol 83. issue 4. 2008-03-26. PMID:18305452. |
nicotine acts on nicotinic cholinergic receptors in the brain to release dopamine and other neurotransmitters that sustain addiction. |
2008-03-26 |
2023-08-12 |
human |
| Mario E Alburges, Amanda J Hoonakker, Glen R Hanso. Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system. European journal of pharmacology. vol 573. issue 1-3. 2008-03-13. PMID:17689525. |
because neurotensin has been linked with both mesolimbic and mesocortical dopamine function, we examined the impact of nicotine treatment on central nervous neurotensin systems by measuring changes in neurotensin tissue content because it has been shown that such changes reflect alterations in release and activity of this peptide system. |
2008-03-13 |
2023-08-12 |
rat |
| Mario E Alburges, Amanda J Hoonakker, Glen R Hanso. Nicotinic and dopamine D2 receptors mediate nicotine-induced changes in ventral tegmental area neurotensin system. European journal of pharmacology. vol 573. issue 1-3. 2008-03-13. PMID:17689525. |
the nicotine-mediated decrease in the neurotensin-like immunoreactivity of the ventral tegmental area was selectively blocked by a specific dopamine d(2), but not a dopamine d(1), receptor antagonist, while mecamylamine attenuated at the low (3.0 mg/kg) and completely blocked at high (6.0 mg/kg) dose this nicotine effect. |
2008-03-13 |
2023-08-12 |
rat |